This site contains promotional content intended for UK Healthcare Professionals and other relevant decision makers | Not a HCP? Visit our  Public Site.
Adverse Event reporting can be found at the bottom of the page | Prescribing Information for the relevant medicine can be found adjacent to the below content and/or in the footer below. 

  • Products
  • Therapy Areas
  • Resources
  • Events & Webinars
  • Learning Zone
  • Podcasts
Resources

Ophthalmology Resources

Learn more about EYLEA® (aflibercept) 8 mg

Ophthalmology Resources Banner

Access the latest resources below to gain further insights into EYLEA® (aflibercept) 8 mg and to support your prescribing decisions.

 

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD), visual impairment due to diabetic macular oedema (DMO) and visual impairment due to macular oedema secondary to retinal vein occlusion (branch, central and hemiretinal RVO).

Clinical value model

Clinical Value Model

 Discover how EYLEA 8 mg impacts capacity and resources for informed decision-making.

Arrange a Session
Formulary guide 2026

Updated Formulary Guide

Access guidance on clinical equivalence and National Health Service (NHS) pricing for EYLEA 8 mg.

Download Here
Costed Integrated Patient Scenario (CIPS) report

Cost Integrated Patient Scenario (CIPS) Report

Learn about the economic benefits of optimal care pathways for patients with nAMD.

Download Here
State of the Nation (SotN) Report

State of the Nation (SotN) Report

Explore insights into current ophthalmology care for patients at risk of vision loss.

Download Here

Abbreviations

DMO, diabetic macular oedema. nAMD, neovascular (wet) age-related macular degeneration. RVO, retinal vein occlusion.

Prescribing information for EYLEA® (aflibercept) can be found here.

PP-EYL-GB-3081 | March 2026

    • 1
      EYLEA® 114.3 mg/mL Summary of Product Characteristics.